跳到內容

腫瘤科(兒科)

免疫治療

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. (開啟新視窗)

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS

來源‎: N Engl J Med 2017;376(9):836-47.

檢索‎: PubMed 28249141

DOI碼‎: 10.1056/NEJMoa1609783

https://www.ncbi.nlm.nih.gov/pubmed/28249141 (開啟新視窗)

Chimeric antigen receptor T cells for sustained remissions in leukemia. (開啟新視窗)

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA

來源‎: N Engl J Med 2014;371(16):1507-17.

檢索‎: PubMed 25317870

DOI碼‎: 10.1056/NEJMoa1407222

https://www.ncbi.nlm.nih.gov/pubmed/25317870 (開啟新視窗)

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. (開啟新視窗)

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA

來源‎: N Engl J Med 2018;378(5):439-48.

檢索‎: PubMed 29385370

DOI碼‎: 10.1056/NEJMoa1709866

https://www.ncbi.nlm.nih.gov/pubmed/29385370 (開啟新視窗)

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. (開啟新視窗)

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE

來源‎: Cancer 2013;119(22):4036-43.

檢索‎: PubMed 24006085

DOI碼‎: 10.1002/cncr.28334

https://www.ncbi.nlm.nih.gov/pubmed/24006085 (開啟新視窗)

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. (開啟新視窗)

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S

來源‎: Clin Cancer Res 2016;22(8):1951-7.

檢索‎: PubMed 26644412

DOI碼‎: 10.1158/1078-0432.CCR-15-1349

https://www.ncbi.nlm.nih.gov/pubmed/26644412 (開啟新視窗)